SLC5A2 and type 1 diabetes mellitus: Although these protocols offer a plausible modality for the management of ketosis in T1D treated with SGLT2-is, it must be remembered that their use has not been validated by RCTs and are currently insufficient to clear the use of these drugs in this population considering the risk of euglycemic DKA.